OncoMatch/Clinical Trials/NCT06810583
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Is NCT06810583 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Dalbavancin and Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) for leukemia.
Treatment: Dalbavancin · Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) — This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy. Primary objective: \- To estimate the rate of bacterial bloodstream infection in pediatric patients with AML or relapsed ALL undergoing chemotherapy receiving dalbavancin-based prophylaxis Secondary objectives: * To describe the population pharmacokinetics of every 28 days dalbavancin up to 12 weeks in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To describe the tolerability of every 28 days dalbavancin prophylaxis in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To describe the acceptability of every 28 days dalbavancin prophylaxis in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To estimate the rates of likely bacterial infections, Clostridioides difficile infection, and febrile neutropenia in pediatric patients receiving dalbavancin-based prophylaxis
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Demographics
Lab requirements
Blood counts
treatment is expected to cause prolonged (> 7 days) severe neutropenia (ANC < 500/ml)
Kidney function
Estimated glomerular filtration rate (EGFR) <30 mL/minute/1.73 m2 [excluded]
Liver function
Alkaline phosphatase, alanine transferase or total bilirubin ≥ 3x upper limit of normal for age [excluded]
Cardiac function
Diagnosed with long QT syndrome [excluded]
treatment is expected to cause prolonged (> 7 days) severe neutropenia (ANC < 500/ml); Alkaline phosphatase, alanine transferase or total bilirubin ≥ 3x upper limit of normal for age; Estimated glomerular filtration rate (EGFR) <30 mL/minute/1.73 m2; Diagnosed with long QT syndrome
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06810583 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 25 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify